PCMC
RXRX icon

Planning Capital Management Corporation’s Recursion Pharmaceuticals RXRX Stock Holding History

Planning Capital Management Corporation’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$53 Hold
8
– – ﹤0.01% 741
2024
Q2 		$60 Buy
+8
New +$70 ﹤0.01% 677

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Planning Capital Management Corporation's RXRX Position: Q3 2024 in Review

Planning Capital Management Corporation held its Recursion Pharmaceuticals (RXRX) position steady in Q3 2024 at 8 shares worth $53. The position accounts for ﹤0.01% of the portfolio, ranked #741.

Planning Capital Management Corporation first reported a position in RXRX in Q2 2024 and has held it in 2 quarters since. The position peaked at $60 in Q2 2024. 267 funds tracked by Wall St. Rank hold RXRX as of Q3 2024.

  • Planning Capital Management Corporation held 8 shares of Recursion Pharmaceuticals worth $53 as of Q3 2024.
  • Planning Capital Management Corporation left its Recursion Pharmaceuticals share count unchanged in Q3 2024.
  • Recursion Pharmaceuticals made up ﹤0.01% of Planning Capital Management Corporation's portfolio in Q3 2024, its #741 holding.
  • Planning Capital Management Corporation first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 2 quarters since.
  • Planning Capital Management Corporation's Recursion Pharmaceuticals position peaked at $60 in Q2 2024.
  • 267 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.